A new agreement with Swiss Regedent AG – breakthrough for RLS and Perisolv on the European market
The Biomedicine company Rubicon Life Science (RLS) has signed a new agreement with Swiss Regeden AG on the sale, distribution and marketing of Perisolv in Germany, Italy, Austria and Switzerland.
? Perisolv is in line with our other product family and will be very important for our global growth strategy, comments Dr. Herbert Früh, CEO of Regedent and with many years’ ex-perience in global life science companies.
Perisolv is a patented biochemical substance used for an efficient and gentle treatment of periodontal disease. Product characteristics are unique in its kind. It softens the degenerated tissue without affecting healthy tissue while working bacteria inhibiting.
? Our Perisolv tests have shown very good results. Therefore, Perisolv will be very im-portant for Regedent’s global growth. It also shows that we have a product portfolio that is at the forefront of medical progress, says Herbert Früh.
The time from first contact to signed contract has been short, and according to Fredrik Florberger, CEO of RLS, the explanation is that the companies have the same view of how the market is going to evolve and what kind of products the customers demand.
? There is a great international interest in Perisolv and in Regedent we get a partner with the right conditions for an international launch. Regedent has an extensive industry knowledge and like us they experience an increasing demand for innovative products with minimal adverse effects, says Fredrik Florberger.
Regedent is a newly formed company (2013) with a very experienced board and owners. This applies particularly to CEO Dr. Herbert Früh, former Managing Director of Geistlich Biomaterials. Later he became Division Manager at the leading global manufacturer of dental implants, Straumann.
To start with the agreement between RLS and Regedent comprises direct sales in Germany, Italy, Austria and Switzerland. Planning for expansion on other markets of interest is already on-going parallel to the start-up in Europe.
? Regedent has already placed an order which alone is worth twice as much as the sale of Persiolv throughout 2013. It makes us very hopeful for Perisolv and RLS in the coming years.
? In connection with the agreement, we established a wholly-owned subsidiary to add activities linked to Perisolv under one hat, says Fredrik Florberger.
For further information, please contact:
Fredrik Florberger
VD, RLS Global AB
Phone: +46 704-58 09 74
E-mail: fredrik.florberger@rubiconlifescience.se
or
Dr Herbert Früh
CEO, Regedent AG
Phone: +41 (79) 642 83 23
E-mail: herbert.frueh@bluewin.ch
Please visit www.perisolv.com, www.carisolvsystem.com, www.minews.se or www.facebook.com/carisolv.